CDD Vault and Kiin Bio team up on AI-linked drug discovery workflows

Collaborative Drug Discovery and Kiin Bio announced a strategic integration on June 11, 2026, connecting CDD Vault with KiinOS to move pre-clinical data into AI-native research workflows. The partnership is designed to help biotech and pharma teams work from a single data layer while speeding analysis, literature review and decision-making.

Why it matters: - The integration links structured experimental data to AI-driven research tools, which can reduce handoffs across drug discovery workflows. - CDD Vault users gain a direct path from registered chemical and biological data to computational analysis, external databases and scientific literature. - The companies are positioning the combined workflow as a way to improve scientific intelligence without forcing R&D teams to rebuild existing processes.

What happened: - Collaborative Drug Discovery and Kiin Bio announced a strategic partnership on June 11, 2026. - The integration connects KiinOS with CDD Vault. - The announcement was made in London. - CDD Vault is used by more than 750 biotechnology and pharmaceutical companies globally. - CDD Vault contains more than 4 billion experimentally validated chemical and biological data points.

The details: - CDD Vault serves as a chemistry and biologics registration and data management system. - The platform supports secure, collaborative data management and analytical tools across the R&D lifecycle. - Kiin Bio describes KiinOS as an AI-native drug discovery platform that executes, reasons over and connects scientific results. - KiinOS is built to work across commercial intelligence, target identification, computational chemistry and bioinformatics. - The integration is intended to let researchers connect pre-clinical discovery data directly into KiinOS workflows. - KiinOS agents gain access to structured, real-time, curated experimental data when the system is deployed. - The goal is to ground recommendations in organization-specific knowledge. - CDD Vault’s modules include Registration, Activity & Visualization, Assays, ELN, Inventory, Curves, AI and Automation.

Between the lines: - The partnership reflects a broader push to make drug discovery systems interoperable instead of siloed. - The companies are betting that AI tools are most useful when they sit on top of trusted internal data, not just public datasets. - Kiin Bio’s pitch is that its platform augments existing R&D teams rather than replacing them, which may appeal to groups that want faster output without adding headcount. - CDD’s role as a source of truth suggests the value proposition is as much about data quality as it is about model capability.

What’s next: - Researchers using CDD Vault will be able to use the integrated workflow as the partnership rolls out. - The companies are expected to use the integration to scale connected scientific intelligence across drug discovery teams. - Future value will likely depend on how well KiinOS turns CDD Vault data into faster decisions, literature exploration and experimental prioritization.

The bottom line: - The partnership ties a large research data platform to an AI-native discovery layer, aiming to make drug discovery workflows faster, more connected and easier to act on.